Pharmaceuticals company Sudeep Pharma announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, revenue stood at Rs 18,233.87 lakh, representing an increase of 5.80% QoQ from Rs 17,233.56 lakh in Q3FY26 and a growth of 15.74% YoY compared to Rs 15,754.65 lakh in Q4FY25. For the full year FY26, revenue reached Rs 64,225.80 lakh, up 27.94% YoY from Rs 50,199.92 lakh in FY25. Total Income: For Q4FY26, total income was Rs 18,876.34 lakh, an increase of 5.35% QoQ and 17.02% YoY. For the full year FY26, total income stood at Rs 67,084.34 lakh, reflecting a 31.20% YoY growth compared to Rs 51,132.83 lakh in FY25. Profit Before Tax (PBT): For Q4FY26, PBT was Rs 6,269.30 lakh, marking a 1.48% QoQ increase and an 8.36% YoY growth. For the full year FY26, PBT reached Rs 22,807.44 lakh, an increase of 24.74% YoY from Rs 18,284.51 lakh. Net Profit for the Period (PAT): For Q4FY26, PAT stood at Rs 4,853.82 lakh, up 1.76% QoQ from Rs 4,769.91 lakh and up 9.85% YoY from Rs 4,418.57 lakh. For the full year FY26, PAT was Rs 17,428.47 lakh, representing a 25.63% YoY increase compared to Rs 13,872.92 lakh in FY25. Total Comprehensive Income: The total comprehensive income for FY26 reached Rs 17,305.95 lakh compared to Rs 13,709.41 lakh in FY25. Standalone Financial Highlights: Revenue from Operations: For Q4FY26, revenue was Rs 8,016.71 lakh, reflecting a decline of 11.20% QoQ and 23.54% YoY. For the full year FY26, revenue stood at Rs 33,850.54 lakh, a decrease of 5.11% YoY from Rs 35,673.18 lakh. Total Income: For Q4FY26, total income was Rs 8,978.62 lakh, down 9.96% QoQ and 16.83% YoY. For the full year FY26, total income increased by 3.26% YoY to Rs 37,700.94 lakh. Profit Before Tax (PBT): For Q4FY26, PBT stood at Rs 3,474.31 lakh, down 5.14% QoQ and 23.27% YoY. For the full year FY26, PBT rose 12.13% YoY to Rs 14,509.69 lakh. Net Profit for the Period (PAT): For Q4FY26, PAT reached Rs 2,576.56 lakh, down 4.11% QoQ and 22.24% YoY. For the full year FY26, standalone PAT grew by 12.36% YoY to Rs 10,758.07 lakh compared to Rs 9,574.77 lakh in FY25. Business Highlights: Dividend: The Board has recommended a Final Dividend of Rs 1.50 (150%) per equity share of Rs 1 each for the year ended March 31, 2026. IPO and Listing: During FY26, the company completed an Initial Public Offering (IPO) of 15,092,749 equity shares at an issue price of Rs 593 per share. The shares were listed on the NSE and BSE on November 28, 2025. Utilization of IPO Proceeds: The company received net proceeds of Rs 8,833.59 lakh. As of March 31, 2026, Rs 1,252.19 lakh was utilized for general corporate purposes. Rs 7,581.40 lakh intended for capital expenditure on machinery remains unutilized and is kept as term deposits in bank. Strategic Acquisition: The company, through its subsidiary, acquired an 85% equity interest in Nutrition Supplier & Services (Ireland) Limited (NSS) for Rs 12,857.63 lakh. NSS became a step-down subsidiary effective May 22, 2025. Segment Performance (Consolidated External Revenue): Pharmaceutical, Food and Nutrition: Revenue for Q4FY26 was Rs 9,009.94 lakh; for the full year FY26, it reached Rs 36,263.91 lakh. Speciality Ingredients: Revenue for Q4FY26 stood at Rs 9,223.93 lakh; for the full year FY26, it was Rs 27,961.89 lakh. Standalone Operations: On a standalone basis, the company operates in a single business segment, which is Pharmaceutical, food and nutrition. Goodwill: Following the NSS acquisition, the company recognized a Goodwill of Rs 6,824.00 lakh in its consolidated results. Employee Benefits: The company noted that the implementation of final Central Rules under new labour codes is being monitored, with no impact on gratuity liability recognized as of March 31, 2026. Result PDF